Cancer Therapy Advisor Contributing Writer

Oncology trial reports written by medical writers are more likely to have surrogate endpoints as the primary endpoint.

The risk of early death in AYAs with cancer depends on the type of malignancy they have as well as multiple demographic factors, a study suggests.